A c-Myc-MicroRNA functional feedback loop affects hepatocarcinogenesis

Hepatology

Volumn 57, Issue 6, 2013, Pages 2378-2389

  Han, Han ^a   Sun, Dan ^a   Li, Wenjuan ^a   Shen, Hongxing ^a   Zhu, Yahui ^a   Li, Chen ^a   Chen, Yuxing ^a   Lu, Longfeng ^a   Li, Wenhua ^a   Zhang, Jinxiang ^b   Tian, Yuan ^a   Li, Youjun ^a  

^a WUHAN UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 148A 5P; MICRORNA 363 3P; MYC PROTEIN; UBIQUITIN; UBIQUITIN SPECIFIC PROTEASE 28; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER PATIENT; CARCINOGENICITY; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; FEEDBACK SYSTEM; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY MECHANISM;

CARCINOMA, HEPATOCELLULAR; CELL CYCLE CHECKPOINTS; CELL TRANSFORMATION, NEOPLASTIC; CONSERVED SEQUENCE; CPG ISLANDS; E-BOX ELEMENTS; FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICRORNAS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MYC; UBIQUITIN THIOLESTERASE;

EID: 84879111668     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26302     Document Type: Article

References (50)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255.
2. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002; 31: 339-346.
3. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-687.
4. Coulouarn C, Factor VM, Conner EA, Thorgeirsson SS. Genomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer. Carcinogenesis 2011; 32: 1434-1440.
5. Thorgeirsson SS. The almighty MYC: orchestrating the micro-RNA universe to generate aggressive liver cancer. J Hepatol 2011; 55: 486-487.
6. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004; 431: 1112-1117.
7. Cairo S, Wang Y, de Reyniès A, Duroure K, Dahan J, Redon MJ, et al. Stem cell-like micro-RNA signature driven by Myc in aggressive liver cancer. Proc Natl Acad Sci U S A 2010; 107: 20471-20476.
8. Dang CV. MYC on the path to cancer. Cell 2012; 149: 22-35.
9. Eilers M, Eisenman RN. Myc's broad reach. Genes Dev 2008; 22: 2755-2766.
10. Bui TV, Mendell JT. Myc: maestro of microRNAs. Genes Cancer 2010; 1: 568-575.
11. Trumpp A, Refaeli Y, Oskarsson T, Gasser S, Murphy M, Martin GR, et al. c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature 2001; 414: 768-773.
12. Baudino TA, McKay C, Pendeville-Samain H, Nilsson JA, Maclean KH, White EL, et al. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev 2002; 16: 2530-2543.
13. Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic disease. Oncogene 1999; 18: 3004-3016.
14. Lin CP, Liu CR, Lee CN, Chan TS, Liu HE. Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J Hepatol 2010; 2: 16-20.
15. Kaposi-Novak P, Libbrecht L, Woo HG, Lee YH, Sears NC, Coulouarn C, et al. Central role of c-Myc during malignant conversion in human hepatocarcinogenesis. Cancer Res 2009; 69: 2775-2782.
16. Terradillos O, Billet O, Renard CA, Levy R, Molina T, Briand P, et al. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene 1997; 14: 395-404.
17. Factor VM, Kao CY, Santoni-Rugiu E, Woitach JT, Jensen MR, Thorgeirsson SS. Constitutive expression of mature transforming growth factor beta1 in the liver accelerates hepatocarcinogenesis in transgenic mice. Cancer Res 1997; 57: 2089-2095.
18. Coulouarn C, Gomez-Quiroz LE, Lee JS, Kaposi-Novak P, Conner EA, Goldina TA, et al. Oncogene-specific gene expression signatures at preneoplastic stage in mice define distinct mechanisms of hepatocarcinogenesis. HEPATOLOGY 2006; 44: 1003-1011.
19. Popov N, Wanzel M, Madiredjo M, Zhang D, Beijersbergen R, Bernards R, et al. The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol 2007; 9: 765-774.
20. Li Y, Lu J, Cohen D, Prochownik EV. Transformation, genomic instability and senescence mediated by platelet/megakaryocyte glycoprotein Ibalpha. Oncogene 2008; 27: 1599-1609.
21. Zhang D, Zaugg K, Mak TW, Elledge SJ. A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response. Cell 2006; 126: 529-542.
22. Napoli S, Pastori C, Magistri M, Carbone GM, Catapano CV. Promoter-specific transcriptional interference and c-myc gene silencing by siRNAs in human cells. EMBO J 2009; 28: 1708-1719.
23. Yi F, Jaffe R, Prochownik EV. The CCL6 chemokine is differentially regulated by c-Myc and L-Myc, and promotes tumorigenesis and metastasis. Cancer Res 2003; 63: 2923-2932.
24. Li YJ, Xu FF, Lu J, Saunders WS, Prochownik EV. Widespread genomic instability mediated by a pathway involving glycoprotein Ib alpha and aurora B kinase. J Biol Chem 2010; 285: 13183-13192.
25. Li Y, Rogulski K, Zhou QS, Sims PJ, Prochownik EV. The negative c-myc target onzin affects proliferation and apoptosis via its obligate interaction with phospholipids scramblase Mol Cell Biol 2006; 26: 3401-3413.
26. Wang H, Hammoudeh DI, Follis AV, Reese BE, Lazo JS, Metallo SJ, et al. Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther 2007; 6: 2399-2408.
27. Mendell JT, Olson EN. MicroRNAs in stress signaling and human disease. Cell 2012; 148: 1172-1187.
28. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet 2011; 12: 861-874.
29. Haggerty TJ, Zeller KI, Osthus RC, Wonsey DR, Dang CV. A strategy for identifying transcription factor binding sites reveals two classes of genomic c-Myc target sites. Proc Natl Acad Sci U S A 2003; 100: 5313-5318.
30. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, et al. Genomic targets of the human c-Myc protein. Genes Dev 2003; 17: 1115-1129.
31. ftp://mirbase.org/pub/mirbase/CURRENT/README. The miRBase Sequence Database, Release 16.
32. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005; 435: 839-843.
33. Chang TC, Yu D, Lee YS, Wentzel EA. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008; 40: 43-50.
34. Chang TC, Zeitels LR, Hwang HW, Gao P, Dang CV, Beer MA, et al. Lin-28B transactivation is necessary for Myc-mediated let-7 repression and proliferation. Proc Natl Acad Sci U S A 2009; 106: 3384-3389.
35. Huang YW, Liu JC, Deatherage DE, Luo J, Mutch DG, Goodfellow PJ, et al. Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res 2009; 69: 9038-9046.
36. Lujambio A, Calin GA, Villanueva A, Ropero S, Blanco D, Faller WJ, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A 2008; 105: 13556-13561.
37. Gao XN, Lin J, Li YH, Gao L, Wang XR, Wang W, et al. MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia. Oncogene 2011; 30: 3416-3428.
38. Chen J, Zhang X, Lentz C, Abi-Daoud M, Paré GC, Yang X, et al. MiR-193b regulates Mcl-1 in melanoma. Am J Pathol 2011; 179: 2162-2168.
39. Coskun E, von der Heide EK, Schlee C, Kühnl A, Gökbuget N, Hoelzer D, et al. The role of microRNA-196a and microRNA-196b as ERG regulators in acute myeloid leukemia and acute T-lymphoblastic leukemia. Leuk Res 2011; 35: 208-213.
40. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009; 138: 592-603.
41. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009; 458: 762-765.
42. Hatziapostolou M, Polytarchou C, Aggelidou E, Drakaki A, Poultsides GA, Jaeger SA, et al. An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis. Cell 2011; 147: 1233-1247.
43. Lee JJ, Drakaki A, Iliopoulos D, Struhl K. MiR-27b targets PPARγ to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells. Oncogene 2012; 31: 3818-3825.
44. Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell 2012; 22: 506-523.
45. Zhang Y, He X, Liu Y, Ye Y, Zhang H, He P, et al. microRNA-320a inhibits tumor invasion by targeting neuropilin 1 and is associated with liver metastasis in colorectal cancer. Oncol Rep 2012; 27: 685-694.
46. Feng M, Li Z, Aau M, Yang X, Yu Q. Myc/miR-378/TOB2/cyclin D1 functional module regulates oncogenic transformation. Oncogene 2011; 30: 2242-2251.
47. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12: 247-256.
48. Dubois NC, Adolphe C, Ehninger A, Wang RA, Robertson EJ, Trumpp A. Placental rescue reveals a sole requirement for c-Myc in embryonic erythroblast survival and hematopoietic stem cell function. Development 2008; 135: 2455-2465.
49. Chan KL, Guan XY, Ng IO. High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma. Hum Pathol 2004; 35: 1324-1331.
50. Ng SB, Yan J, Huang G, Selvarajan V, Tay JL, Lin B, et al. Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma. Blood 2011; 118: 4919-4929.